CORDIS
EU research results

CORDIS

English EN

Targeting newly discovered oxygen-sensing cascades for novel cancer treatments Biology, equipment, drug candidates.

Project information

Grant agreement ID: 502932

  • Start date

    1 February 2004

  • End date

    31 January 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 9 918 380

  • EU contribution

    € 8 000 000

Coordinated by:

AALBORG UNIVERSITY

Denmark

Objective

The last decade's basic and clinical oncology research has revealed a number of so far unrecognised regulating responses (e.g. HIF-1) in cells exposed to hypoxia. These processes have been proven highly important for embryonic development and survival and seem to have a major impact on tumour progression and resistance to radiotherapy and certain types of chemotherapy. Because of their strong over-expression in solid cancer tumours in comparison to adjacent normal tissue of these processes, this new knowledge may open a therapeutic window for cancer treatment by utilising hypoxia-responsive processes as drug targets.

Major EU stakeholders in academic research and industry will therefore explore and validate these new molecular targets as a necessary step in the preclinical development of innovative new diagnostics and treatment.

Our committee has identified the outstanding basic problems to be solved over the first 2 to 3 years in order to allow a successful drug development. These include: dissection of relevant steps in cancer cell response to hypoxia, development of the technology platform needed, further identification and characterisation ofmarker/target molecules, and initial in vitro drug development. Our own mid-term evaluation will then select which hypoxic processes may be suitable as targets for cancer-specific treatment.

Simultaneously, we will study diagnostic tagging and therapeutic strategies leading up to a selection process of promising compounds to be further developed after the end of the project period. The new treatments will be developed along two lines: targeting known cytostatics towards the newly discovered hypoxia-responsive molecules and searching for so far unused compounds, preferably toxic to pathways active during hypoxia. The final effort will be to ensure continued (EU) industry utilisation of our results.

Coordinator

AALBORG UNIVERSITY

Address

Fredrik Bajers Vej 5
Aalborg

Denmark

Participants (25)

ALBERT LUDWIGS UNIVERSITY FREIBURG

Germany

ASTRAZENECA UK LIMITED

United Kingdom

AVENTIS PHARMA

France

CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN, CAMPUS VIRCHOW KLINIKUM, BERLIN, GERMANY

Germany

DEUTSCHES HERZZENTRUM MÜNCHEN, KLINIK AN DER TU MÜNCHEN

Germany

FRIEDRICH-ALEXANDER-UNIVERSITÄT ERLANGEN-NÜRNBERG

Germany

IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE

United Kingdom

INSTITUTE OF BIOTECHNOLOGY

Lithuania

INSTITUTE OF VIROLOGY, SLOVAK ACADEMY OF SCIENCES

Slovakia

JOBST TECHNOLOGIES GMBH

Germany

KAROLINSKA INSTITUTET

Sweden

LEA MEDIZINTECHNIK GMBH

Germany

LEO PHARMA A/S

Denmark

MAASTRO INNOVATIONS BV

Netherlands

OXFORD BIOMEDICA PLC

United Kingdom

RINA-NETZWERK RNA TECHNOLOGIEN GMBH

Germany

THE UNIVERSITY OF OSLO

Norway

THE VICTORIA UNIVERSITY OF MANCHESTER

United Kingdom

ULLEVÅL UNIVERSITY HOSPITAL

Norway

UNIVERSITEIT MAASTRICHT/RESEARCH INSTITUTE GROW

Netherlands

UNIVERSITY COLLEGE LONDON

United Kingdom

UNIVERSITY OF FLORENCE, DEPARTMENT OF CHEMISTRY

Italy

UNIVERSITY OF ZURICH

Switzerland

VIVOX APS

Denmark

Project information

Grant agreement ID: 502932

  • Start date

    1 February 2004

  • End date

    31 January 2009

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 9 918 380

  • EU contribution

    € 8 000 000

Coordinated by:

AALBORG UNIVERSITY

Denmark